Patents Assigned to New York Blood Center, Inc.
  • Patent number: 6323012
    Abstract: The present invention provides a method for treating a viral infection in a subject. The method comprises administering to the subject an amount of 5-aminolevulinic acid to cause virus-infected cells to accumulate protoporphyrin in amounts such that upon application of a sufficient dose of red light, the virus-infected, protoporphyrin-accumulated cells will be destroyed; and applying a sufficient dose of red light to the virus-infected, protoporphyrin-accumulated cells to destroy the virus-infected, protoporphyrin-accumulated cells.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: November 27, 2001
    Assignees: New York Blood Center, Inc., Bar-Ilan University
    Inventors: Ehud Ben-Hur, Zvi Malik
  • Patent number: 6294361
    Abstract: The present invention concerns a process for inactivating an extracellular lipid enveloped human pathogenic virus and/or an intracellular human pathogenic virus which may be present in a blood cell composition containing ≧1×109 cells/ml by contacting that composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of ≧630 nm, light and oxygen and/or a quencher. In one embodiment of the invention, the process is conducted under conditions whereby a structural integrity of greater than 80% of at least one type of blood cell contained within said composition is retained.
    Type: Grant
    Filed: October 26, 1997
    Date of Patent: September 25, 2001
    Assignee: New York Blood Center, Inc.
    Inventors: Bernard Horowitz, Jay E. Valinsky, Nicholas E. Geacintov, Bolanle Williams, Shanti B. Rywkin, Henrietta Nunno
  • Patent number: 6274308
    Abstract: The invention relates to a method for purifying of a nucleic acid from a biological sample. The method involves contacting a biological sample containing a nucleic acid with a hydrophilic polyvinylidene fluoride (PVDF) membrane which contains pores having an average diameter less than about 0.45 &mgr;m and recovering the nucleic acid. The method can further include adding silica beads to the biological sample prior to the contacting step.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: August 14, 2001
    Assignee: New York Blood Center, Inc.
    Inventors: Dong-Hun Lee, Alfred M. Prince
  • Patent number: 6245890
    Abstract: The present invention provides a porcine antigen that binds to human xenoreactive antibodies. The porcine antigen differs from the known porcine xenoantigens in that the antigen does not include an &agr;Gal epitope. The present invention also provides methods to purify the porcine antigen of the invention, as well as agents that bind to the antigen. The antigen may be used to generate antibodies against the antigen. The antigen is useful for detecting the presence of human xenoreactive antibodies against the antigen in blood and blood compositions, and antibodies against the antigen may be used to detect the presence of the antigen in samples. The invention also provides methods and pharmaceutical compositions for reducing a host rejection response to a porcine xenograft. Finally, a method to treat human blood or blood-derived compositions to reduce the level of human xenoantibodies is disclosed.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: June 12, 2001
    Assignee: New York Blood Center, Inc.
    Inventor: Alex Zhu
  • Patent number: 6228631
    Abstract: This invention relates to a recombinant enzyme for use in the removal of A antigens from the surface of cells in blood products. Specifically, this invention is directed to a recombinant &agr;-N-acetylgalactosaminidase enzyme from chicken liver, methods of cloning and expressing said recombinant &agr;-N-acetylgalactosaminidase enzyme and a method of removing A antigens from the surface of cells in blood products using said recombinant &agr;-N-acetylgalactosaminidase enzyme.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: May 8, 2001
    Assignee: New York Blood Center, Inc.
    Inventors: Alex Zhu, Jack Goldstein
  • Patent number: 6221643
    Abstract: The present invention provides a method for diagnosing BS as well as determining whether a subject is a carrier of a mutated BLM gene. The present invention also provides one or more single-stranded nucleic acid probes and antibodies which may be formulated in kits, and used for diagnosing BS or determining whether a subject is a carrier of a mutated BLM gene. In addition, the present invention provides a method for treating or preventing the onset of BS in a subject in need of such treatment or prevention, as well as vectors and stem cells useful for such treatment or prevention. The present invention also provides a purified and isolated nucleic acid encoding an enzymatically active BLM protein, a vector comprising this nucleic acid, a cell stably transformed with this vector, as well as a method for producing recombinant, enzymatically active BLM protein. A purified, enzymatically active BLM protein is also provided by the present invention.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: April 24, 2001
    Assignee: New York Blood Center, Inc.
    Inventors: Nathan Ellis, James German, Joanna Groden
  • Patent number: 6214534
    Abstract: The present invention concerns the product produced by inactivating extracellular or intracellular pathogenic virus in a biological composition without incurring substantial disruption or inactivation of cells and without significant loss of labile proteins or other valuable biological components also contained therein, the inactivation process comprising subjecting said composition to a virucidally effective amount of irradiation in the presence of (a) a mixture of a compound that quenches type I photodynamic reactions and a compound that quenches type II photodynamic reactions or (b) a bifunctional compound that is capable of quenching both type I and type II reactions, to thereby inactivate said virus while retaining functionality of said composition. The composition is advantageously subjected to the irradiation and the mixture of compounds or bifunctional compound in the presence of an irradiation sensitizer.
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: April 10, 2001
    Assignee: New York Blood Center, Inc.
    Inventors: Bernard Horowitz, Bolanle Williams, Henrietta Margolis-Nunno, Sing N. Chin
  • Patent number: 6171810
    Abstract: A method for detecting and measuring exoglycosidase activity is presented. The method employs derivatives containing the fluorescent group 4-methylumbelliferyl (“4-Mu”) at a pH lower than that conventionally employed. While the fluorescence intensity due to the 4-Mu group is considerably diminished at the lower pHs employed, the fluorescence intensity is still sufficient to continuously measure exoglycosidase activity in the activity range commonly assayed. The method is easily adaptable to high throughput enzyme assay systems and automated data analysis method. The method also provides a means to detect alterations in exoglycosidase activity that are independent of expression levels.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: January 9, 2001
    Assignee: New York Blood Center, Inc.
    Inventor: Alex Zhu
  • Patent number: 6165493
    Abstract: A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: December 26, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Shibo Jiang, Asim Kumar Debnath, Nathan Strick, Gordon Jay Dow
  • Patent number: 6159733
    Abstract: The present invention provides a method for photoinactivating malignant cells in a cell sample. The method comprises incubating the cell sample with a concentration of Pc 4 effective to cause a substantial number of the malignant cells contained in the cell sample to absorb Pc 4 such that upon application of a sufficient dose of red light, the Pc 4 absorbed malignant cells will be photoinactivated; and applying a sufficient dose of red light to the cell sample to photoinactivate the Pc 4 absorbed malignant cells contained in the cell sample.
    Type: Grant
    Filed: June 20, 1996
    Date of Patent: December 12, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Ehud Ben-Hur, Robert A. Preti, Jan F. Keij
  • Patent number: 6143287
    Abstract: The present invention provides a method for removing hair from a selected skin area comprising the steps of (a) applying a liposome composition comprising a photosensitizer to the selected skin area so that the composition is introduced into hair follicle ducts of the skin area, wherein the photosensitizer is present in the composition in an amount effective to undergo a reaction and damage the hair follicles upon application to the skin area of light at an appropriate wavelength, energy and duration to penetrate the skin and activate the photosensitizer; (b) removing from the skin area substantially all of the liposome composition which is not introduced into the hair follicle ducts; and (c) applying light to the skin area at an appropriate wavelength, energy and duration to penetrate the skin and cause the photosensitizer to undergo a reaction to damage the hair follicles. The present invention also provides a composition useful for hair removal.
    Type: Grant
    Filed: February 27, 1996
    Date of Patent: November 7, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Ehud Ben-Hur, Maria M. Zuk, Wai-Shun Chan
  • Patent number: 6120996
    Abstract: A method of identification of differentially expressed messenger RNA (mRNA) which consists of synthesizing from a set of sequences of mRNA sets of fragments of complementary DNA (cDNA), which are separated with the aid of gel electrophoresis and the pictures of separation of the cDNA from different types of cells are compared and fragments with differential signal intensity are identified. For formation of the set of fragments the cDNA is cleaved with the aid of restriction nucleases. A method of cloning of differentially expressed mRNAs consists of synthesizing from sets of sequences of mRNAs from different types of cells sets of fragments of complementary DNA (cDNA) which are separated with the aid of gel electrophoresis, the pictures of the separation of the cDNA from different types of cells are compared, fragments of cDNA with different signal intensities are separated from the gel, amplified with the aid of a polymerase chain reaction and cloned to a plasmid or phage vector.
    Type: Grant
    Filed: November 6, 1997
    Date of Patent: September 19, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander V. Belyavsky, Natalia B. Ivanova
  • Patent number: 6103706
    Abstract: The present invention provides a method for treating a viral infection in a subject in need of such treatment comprising administering to the subject a photosensitizer formulated in a liposome carrier, and exposing the subject to light at a wavelength 20-40 nm greater than the maximum absorption of the photosensitizer at a sufficient dose and duration to treat the viral infection in the subject. The present invention also provides a method for treating a viral infection in a subject in need of such treatment comprising administering to the subject (i) a photosensitizer formulated in a liposome carrier and (ii) at least one quencher, and exposing the subject to light at a sufficient wavelength, dose and duration to treat the viral infection in the subject.
    Type: Grant
    Filed: April 29, 1997
    Date of Patent: August 15, 2000
    Assignee: New York Blood Center, Inc.
    Inventor: Ehud Ben-Hur
  • Patent number: 6090599
    Abstract: Disclosed are two processes.
    Type: Grant
    Filed: September 1, 1998
    Date of Patent: July 18, 2000
    Assignee: New York Blood Center, Inc.
    Inventor: Ehud Ben-Hur
  • Patent number: 6087141
    Abstract: The present invention concerns a process for inactivating extracellular and intracellular virus in a biological composition without incurring substantial disruption or inactivation thereof, said process comprising subjecting said composition to a virucidally effective amount of UVA1 irradiation substantially in the absence of UVA2 irradition for a period of time sufficient to thereby inactivate said virus while retaining functionality of said composition. The biological composition is advantageously a product that contains red blood cells or platelets. The process is advantageously carried out in the presence of an irradiation sensitizer compound and/or a quencher. The present invention also concerns the product substantially identical to that produced bythe inventive process.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: July 11, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Henrietta Margolis-Nunno, Ehud Ben-Hur, Bernard Horowitz
  • Patent number: 6077659
    Abstract: An improved process is disclosed for photodynamically inactivating viruses in red blood cell containing compositions by adding vitamin E or a derivative thereof, such as Trolox, to the red blood cell and photosensitizer containing composition prior to irradiation. Addition of vitamin E or derivative thereof is protective of the red blood cells but not the viruses to be inactivated. Cells irradiated in this manner exhibit reduced leakage of potassium ion, and reduced loss of negative charges from the cell membrane compared to cells treated in the absence of vitamin E or derivative. Red blood cells sterilized by this method are better preserved during storage and their life-time in the circulation in vivo is enhanced.
    Type: Grant
    Filed: November 16, 1994
    Date of Patent: June 20, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Ehud Ben-Hur, Shanti Rywkin, Bernard Horowitz
  • Patent number: 6074837
    Abstract: An assay method that requires a soluble fibrin monomer or a soluble fibrin monomer reagent as one of the components of the assay. The reagent is a fibrin-like material having a solubility and stability similar to fibrinogen in that it remains soluble and stable at physiological conditions at a concentration employed in the assay in the absence of fibrin polymerization inhibitors or reagents for maintaining solubility.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 13, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Roman Procyk, Bohdan J. Kudryk
  • Patent number: 6063592
    Abstract: A method for cleaving polypeptides includes contacting a polypeptide with a recombinant or isolated Kell protein having proteolytic activity for the polypeptide. A method for converting big endothelins-1, -2 and -3 to endothelins-1, -2 and -3 respectively comprises contacting the big endothelin with Kell protein having proteolytic activity for cleaving big endothelin-1, -2 and -3 to endothelin-1, -2 or -3 respectively. In another embodiment, the Kell protein cleaves vasoactive intestinal peptide.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: May 16, 2000
    Assignee: New York Blood Center, Inc.
    Inventor: Soohee Lee
  • Patent number: 6054632
    Abstract: The invention relates to a method for making monoclonal antibodies having pre-defined specificity for an epitope characteristic of or unique to a single form of a polymorphic protein. The method includes constructing a first transgenic animal to express a first form of a polymorphic protein encoded by a first allele of a gene encoding the protein; constructing a second transgenic animal to express a second form of the polymorphic protein encoded by a second allele of the gene encoding the protein; and immunizing the first transgenic animal with cells from the second transgenic animal expressing the second form of the polymorphic protein to induce an immune response in the first transgenic animal yielding an antibody specific for an epitope peculiar to the second form of the polymorphic protein. The invention further includes hybridoma cells secreting a monoclonal antibody specific for the second form of the protein.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: April 25, 2000
    Assignee: New York Blood Center, Inc.
    Inventor: Marion E. Reid
  • Patent number: 6025148
    Abstract: The invention provides monospecific antibodies which are specifically reactive with the .alpha.hd E subunit of fibrinogen or a fragment thereof, but not with other portions of the fibrinogen molecule. The invention also provides anti-.alpha..sub.E probes, including monospecific anti-.alpha..sub.E antibodies which have been detectably labeled. In addition, the invention provides methods of using the monospecific antibodies for detection of the .alpha..sub.E subunit and fragments thereof, as well as reagents and kits for performing the methods. Diagnostic methods for determining information associated with atherogenesis and/or thrombogenesis, as well as for determining information associated with pregnancy status or outcome. The invention further provides continuous cell lines which produce monospecific anti-.alpha..sub.E antibodies.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: February 15, 2000
    Assignee: New York Blood Center, Inc.
    Inventors: Gerd Grieninger, Yiping Fu, Yan Cao, Mohamad Zaher Ahadi, Bohdan J. Kudryk